Sun Pharma’s CEQUA shows sustained dry eye disease improvement in Phase 4 study
Sun Pharmaceutical Industries Limited has made a significant announcement regarding its groundbreaking product, CEQUA (cyclosporine ophthalmic solution) 0.09%. The company has unveiled Phase 4 data showcasing CEQUA’s exceptional ability to induce sustained improvement in the signs and symptoms of dry eye disease (DED). CEQUA is an immunosuppressant and calcineurin inhibitor designed to enhance tear production […]